Congress Approves Continuing Resolution to Fund NIH Through February 18

With just hours to spare before its December 3 deadline, Congress averted a government shutdown and passed a continuing resolution (CR) that will fund the government at the previous year’s level through February 18, 2022. We appreciate the Endocrine Society members who participated in our online campaign, which helped avoid a destabilizing shutdown and ensured that Congress understood the consequences of a CR for the endocrine research community.

However, our work is not done.

The CR is a temporary funding measure that allows the government to keep operating, but for most federal programs, including the National Institutes of Health (NIH), funding is held to this year’s level and there are no increases.

With continued advocacy by our members, we believe we can influence Congress to support research funding.

To ensure that the NIH receives the funding increases that the House and Senate have previously agreed to, the Endocrine Society will continue to advocate for Congress to pass a final appropriations bill for the remainder of FY22 with an increase for the NIH before the February 18 deadline.

Be on the lookout at the beginning of 2022 as we launch a new online campaign. With continued advocacy by our members, we believe we can influence Congress to support research funding.

Please see endocrine.org/takeaction for more details.

You may also like

  • Endocrine Society Advocacy Updates

    Endocrine Society Endorses Right to IVF Act  In June 2024, the Endocrine Society endorsed the Right to IVF Act, introduced by Senators Cory Booker (D-NJ), Patty Murray (D-WA), and Tammy Duckworth (D-IL) to protect and expand nationwide access to fertility treatment, including in vitro fertilization (IVF). The Right to IVF Act would help individuals and families…

  • August 2024 Endocrine Society Advocacy Update

    Revised Version of TROA Passes House Ways & Means Committee On June 27, 2024, the House Ways and Means Committee passed a revised version of the Treat and Reduce Obesity Act (TROA), legislation that would allow Medicare coverage of anti-obesity medications (AOMs), which currently is prohibited under law. The version that passed would only allow…

Find more in